Perioperative Haemostasis, Procedure-Related Pain After Physiological or Pharmacological Modifications of Local Anaesthesia Around the Eyes (P4LE)
Perioperative Haemostasis, Procedure-Related Pain After Physiological or Pharmacological Modifications of Local Anaesthesia Around the Eyes (P4LE) - a Double-Masked, Split-Face, Active-Controlled, Pilot Randomised Clinical Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The aim of the project is to test the hypothesis that the following modifications during subcutaneous eyelid injection of local anaesthesia, compared to 2% lignocaine with 1:200,000 adrenaline, reduce injection pain and procedure-related pain and improve perioperative haemostasis.
- Buffering of 2% lignocaine with 1:200,000 adrenaline by adding sodium bicarbonate;
- Warming of 2% lignocaine with 1:200,000 adrenaline to 37°C;
- Addition of hyaluronidase to 2% lignocaine with 1:200,000 adrenaline; and
- Addition of tranexamic acid to 2% lignocaine with 1:200,000 adrenaline.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Anson Chun Long Wu
- Phone Number: +852 35052878
- Email: wcl589@ha.org.hk
Study Locations
-
-
-
Hong Kong, Hong Kong
- Prince of Wales Hospital
-
Contact:
- Anson Chun Long Wu
- Phone Number: +852 35052878
- Email: wcl589@ha.org.hk
-
Principal Investigator:
- Kelvin Kam Lung Chong
-
Hong Kong, Hong Kong
- Alice Ho Miu Ling Nethersole Hospital
-
Contact:
- Anson Chun Long Wu
- Phone Number: +852 35052878
- Email: wcl589@ha.org.hk
-
Principal Investigator:
- Anson Chun Long Wu
-
Hong Kong, Hong Kong
- CUHK Medical Centre
-
Contact:
- Kelvin Kam Lung Chong
- Phone Number: +852 39435824
- Email: chongkamlung@cuhk.edu.hk
-
Principal Investigator:
- Kelvin Kam Lung Chong
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients undergoing bilateral upper eyelid blepharoplasty requiring subcutaneous anaesthesia at Prince of Wales Hospital, Alice Ho Miu Ling Nethersole Hospital and CUHK Medical Centre; and
- Adult patients aged 18 or above.
Exclusion Criteria:
- Patients aged less than 18;
- Pregnancy;
- Allergy to local anaesthetic agents;
- History of previous eyelid surgery; and
- Patients on antiplatelets or anticoagulants.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: First stage: Buffered
One eyelid: lignocaine buffered with sodium bicarbonate; the other eyelid: unmodified solution of lignocaine
|
Lignocaine buffered with sodium bicarbonate
2% lignocaine with 1:200,000 adrenaline
|
|
Experimental: First stage: Warmed
One eyelid: lignocaine warmed to body temperature; the other eyelid: unmodified solution of lignocaine at room temperature
|
2% lignocaine with 1:200,000 adrenaline
Lignocaine warmed to body temperature
|
|
Experimental: First stage: Hyaluronidase
One eyelid: lignocaine with hyaluronidase added; the other eyelid: unmodified solution of lignocaine
|
2% lignocaine with 1:200,000 adrenaline
Lignocaine with hyaluronidase added
|
|
Experimental: First stage: Tranexamic acid
One eyelid: lignocaine with tranexamic acid added; the other eyelid: unmodified solution of lignocaine
|
2% lignocaine with 1:200,000 adrenaline
Lignocaine with tranexamic acid added
|
|
Experimental: Second stage: Most effective modification A versus B
One eyelid: modification A; the other eyelid: modification B
|
Lignocaine buffered with sodium bicarbonate
2% lignocaine with 1:200,000 adrenaline
Lignocaine warmed to body temperature
Lignocaine with hyaluronidase added
Lignocaine with tranexamic acid added
|
|
Experimental: Second stage: Most effective modification A+B versus A
One eyelid: modification A+B; the other eyelid: modification A
|
Lignocaine buffered with sodium bicarbonate
2% lignocaine with 1:200,000 adrenaline
Lignocaine warmed to body temperature
Lignocaine with hyaluronidase added
Lignocaine with tranexamic acid added
|
|
Experimental: Second stage: Most effective modification A+B versus B
One eyelid: modification A+B; the other eyelid: modification B
|
Lignocaine buffered with sodium bicarbonate
2% lignocaine with 1:200,000 adrenaline
Lignocaine warmed to body temperature
Lignocaine with hyaluronidase added
Lignocaine with tranexamic acid added
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain of injection of local anaesthesia
Time Frame: Within 1 minute after injection of local anaesthesia
|
Pain of injection of local anaesthesia, measured by a pain rating visual analogue scale of minimum 0 to maximum 10 (10 refers to worst pain)
|
Within 1 minute after injection of local anaesthesia
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain encountered during the surgery
Time Frame: Within 15 minutes after surgery
|
Pain encountered during the surgery, measured by a pain rating visual analogue scale of minimum 0 to maximum 10 (10 refers to worst pain)
|
Within 15 minutes after surgery
|
|
Pain encountered one week after surgery
Time Frame: One week after surgery
|
Pain encountered one week after surgery, measured by a pain rating visual analogue scale of minimum 0 to maximum 10 (10 refers to worst pain)
|
One week after surgery
|
|
Postoperative ecchymosis at one week after surgery
Time Frame: One week after surgery
|
Postoperative ecchymosis at one week after surgery, rated based on clinical photos using a standardised rating score of minimum 0 to maximum 5 (5 refers to worst ecchymosis)
|
One week after surgery
|
|
Postoperative swelling at one week after surgery
Time Frame: One week after surgery
|
Postoperative swelling at one week after surgery, rated based on clinical photos using a standardised rating score of minimum 0 to maximum 5 (5 refers to worst swelling)
|
One week after surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Chair: Kelvin Kam Lung Chong, Prince of Wales Hospital, Shatin, Hong Kong
- Principal Investigator: Anson Chun Long Wu, Prince of Wales Hospital, Shatin, Hong Kong
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neurologic Manifestations
- Genetic Diseases, Inborn
- Connective Tissue Diseases
- Skin Diseases
- Skin Diseases, Genetic
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- Pathological Conditions, Signs and Symptoms
- Skin and Connective Tissue Diseases
- Signs and Symptoms
- Pain
- Cutis Laxa
- Organic Chemicals
- Carboxylic Acids
- Anilides
- Amides
- Aniline Compounds
- Amines
- Acetanilides
- Glycoside Hydrolases
- Hydrolases
- Enzymes
- Enzymes and Coenzymes
- Polysaccharide-Lyases
- Carbon-Oxygen Lyases
- Lyases
- Inorganic Chemicals
- Acids, Carbocyclic
- Cyclohexanecarboxylic Acids
- Sodium Compounds
- Carbon Compounds, Inorganic
- Carbonates
- Carbonic Acid
- Bicarbonates
- Tranexamic Acid
- Lidocaine
- Hyaluronoglucosaminidase
- Sodium Bicarbonate
Other Study ID Numbers
Other Study ID Numbers
- CREC-2025.390
- 13242776 (Other Grant/Funding Number: Health Bureau)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.